Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The company is headquartered in Germantown, Maryland and currently employs 160 full-time employees. The company went IPO on 2013-08-08. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Dr. Helen Sabzevari is the President of Precigen Inc, joining the firm since 2017.
What is the price performance of PGEN stock?
The current price of PGEN is $4.35, it has tăng lên 0.23% in the last trading day.
What are the primary business themes or industries for Precigen Inc?
Precigen Inc belongs to Biotechnology industry and the sector is Health Care
What is Precigen Inc market cap?
Precigen Inc's current market cap is $1.5B
Is Precigen Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Precigen Inc, including 2 strong buy, 6 buy, 2 hold, 0 sell, and 2 strong sell